Breast pericanalicular fibroadenoma

Summary

Breast pericanalicular fibroadenoma (MONDO:0002371) is a disease. A subtype of breast fibroadenoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	breast pericanalicular fibroadenoma
Mondo ID	MONDO:0002371
DOID	DOID:2639
ICD-11	687161475
NCIT	C4272
UMLS	C0334497
MedGen	90794
Is cancer (heuristic)	no

Also known as: breast pericanalicular fibroadenoma · pericanalicular breast fibroadenoma · pericanalicular fibroadenoma · pericanalicular fibroadenoma (morphologic abnormality) · pericanalicular fibroadenoma of breast · pericanalicular fibroadenoma of the breast

Disease family

This is a subtype of breast fibroadenoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › thoracic benign neoplasm › breast benign neoplasm › breast fibroadenoma › breast pericanalicular fibroadenoma

Related subtypes (2): breast intracanalicular fibroadenoma, breast giant fibroadenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.